Ortin Global (ORTINGLOBE) Stock Overview
Engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ORTINGLOBE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Ortin Global Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹14.42 |
| 52 Week High | ₹19.90 |
| 52 Week Low | ₹10.01 |
| Beta | 0.55 |
| 1 Month Change | -14.67% |
| 3 Month Change | 7.05% |
| 1 Year Change | 35.40% |
| 3 Year Change | -25.09% |
| 5 Year Change | -51.45% |
| Change since IPO | -46.96% |
Recent News & Updates
Recent updates
Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention Today
Jan 24
Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?
Dec 27
Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Nov 30Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load
Sep 15Shareholder Returns
| ORTINGLOBE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.2% | 2.7% | 6.9% |
| 1Y | 35.4% | 5.1% | 7.0% |
Return vs Industry: ORTINGLOBE exceeded the Indian Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: ORTINGLOBE exceeded the Indian Market which returned 7% over the past year.
Price Volatility
| ORTINGLOBE volatility | |
|---|---|
| ORTINGLOBE Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 10.3% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: ORTINGLOBE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ORTINGLOBE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 3 | Sanka Murali Murthy | www.ortinlabsindia.com |
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products.
Ortin Global Limited Fundamentals Summary
| ORTINGLOBE fundamental statistics | |
|---|---|
| Market cap | ₹106.20m |
| Earnings (TTM) | -₹8.95m |
| Revenue (TTM) | ₹1.12m |
Is ORTINGLOBE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORTINGLOBE income statement (TTM) | |
|---|---|
| Revenue | ₹1.12m |
| Cost of Revenue | ₹860.00k |
| Gross Profit | ₹257.00k |
| Other Expenses | ₹9.21m |
| Earnings | -₹8.95m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 23.01% |
| Net Profit Margin | -801.43% |
| Debt/Equity Ratio | 71.6% |
How did ORTINGLOBE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 22:55 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ortin Global Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.